Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration
<b>Background:</b> Dry age-related macular degeneration (AMD) is one of the leading causes of vision loss in older patients. The macula accumulates drusen with loss of retinal pigment epithelial cells and photoreceptors. Abnormal subretinal neovascularization is absent. There is no effec...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Medicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2305-6320/7/4/16 |
id |
doaj-d2ca955c8e6c461ba5a2ad51c7603187 |
---|---|
record_format |
Article |
spelling |
doaj-d2ca955c8e6c461ba5a2ad51c76031872020-11-25T02:05:33ZengMDPI AGMedicines2305-63202020-03-017161610.3390/medicines7040016Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular DegenerationJeffrey N. Weiss0Steven Levy1The Healing Institute, 1308 North State Road #7, Suite A/B, Margate, FL 33063, USAMD Stem Cells, 3 Sylvan Road South, Westport, CT 06880, USA<b>Background:</b> Dry age-related macular degeneration (AMD) is one of the leading causes of vision loss in older patients. The macula accumulates drusen with loss of retinal pigment epithelial cells and photoreceptors. Abnormal subretinal neovascularization is absent. There is no effective drug therapy for dry AMD and a large proportion of patients progress to legal blindness from macular atrophy. The Stem Cell Ophthalmology Treatment Study (SCOTS) was conducted to assess the effect of bone marrow-derived stem cells (BMSCs) on dry AMD and other retinal and optic nerve diseases. <b>Methods:</b> Thirty-two eyes were treated with BMSC per the protocols in SCOTS. Provision of BMSCs in Arm 1 was via retrobulbar (RB), sub-tenons (ST) and intravenous (IV); Arm 2 via intravitreal, RB, ST and IV; Arm 3 via subretinal and IV. Patient age averaged 78 years old and ranged from 69 to 90. Visual acuity preoperatively ranged from counting fingers to 20/50-2 with an average preoperative LogMAR of 1.125. <b>Results:</b> Following treatment, 20 of 32 (63%) of eyes experienced improvement in visual acuity averaging 27.6% on LogMAR and ranging from 2.5% to 44.6%. The mean improvement in LogMAR was 0.963 with a standard deviation (SD) of 0.42. The visual acuity remained stable in 34% of treated eyes. One eye continued to worsen as a consequence of disease progression. The results showed high statistical significance with <i>p</i> ≤ 0.001. The procedures were conducted safely, and no complications were observed. <b>Conclusion:</b> Treatment of dry AMD with BMSC using the protocols developed in the SCOTS clinical trial has shown statistically significant clinical benefit improving visual acuity and potentially delaying visual loss in the disease.https://www.mdpi.com/2305-6320/7/4/16maculadegenerationretinastem cellsbone marrow stem cellsAMD |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jeffrey N. Weiss Steven Levy |
spellingShingle |
Jeffrey N. Weiss Steven Levy Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration Medicines macula degeneration retina stem cells bone marrow stem cells AMD |
author_facet |
Jeffrey N. Weiss Steven Levy |
author_sort |
Jeffrey N. Weiss |
title |
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration |
title_short |
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration |
title_full |
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration |
title_fullStr |
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration |
title_full_unstemmed |
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration |
title_sort |
stem cell ophthalmology treatment study (scots): bone marrow-derived stem cells in the treatment of age-related macular degeneration |
publisher |
MDPI AG |
series |
Medicines |
issn |
2305-6320 |
publishDate |
2020-03-01 |
description |
<b>Background:</b> Dry age-related macular degeneration (AMD) is one of the leading causes of vision loss in older patients. The macula accumulates drusen with loss of retinal pigment epithelial cells and photoreceptors. Abnormal subretinal neovascularization is absent. There is no effective drug therapy for dry AMD and a large proportion of patients progress to legal blindness from macular atrophy. The Stem Cell Ophthalmology Treatment Study (SCOTS) was conducted to assess the effect of bone marrow-derived stem cells (BMSCs) on dry AMD and other retinal and optic nerve diseases. <b>Methods:</b> Thirty-two eyes were treated with BMSC per the protocols in SCOTS. Provision of BMSCs in Arm 1 was via retrobulbar (RB), sub-tenons (ST) and intravenous (IV); Arm 2 via intravitreal, RB, ST and IV; Arm 3 via subretinal and IV. Patient age averaged 78 years old and ranged from 69 to 90. Visual acuity preoperatively ranged from counting fingers to 20/50-2 with an average preoperative LogMAR of 1.125. <b>Results:</b> Following treatment, 20 of 32 (63%) of eyes experienced improvement in visual acuity averaging 27.6% on LogMAR and ranging from 2.5% to 44.6%. The mean improvement in LogMAR was 0.963 with a standard deviation (SD) of 0.42. The visual acuity remained stable in 34% of treated eyes. One eye continued to worsen as a consequence of disease progression. The results showed high statistical significance with <i>p</i> ≤ 0.001. The procedures were conducted safely, and no complications were observed. <b>Conclusion:</b> Treatment of dry AMD with BMSC using the protocols developed in the SCOTS clinical trial has shown statistically significant clinical benefit improving visual acuity and potentially delaying visual loss in the disease. |
topic |
macula degeneration retina stem cells bone marrow stem cells AMD |
url |
https://www.mdpi.com/2305-6320/7/4/16 |
work_keys_str_mv |
AT jeffreynweiss stemcellophthalmologytreatmentstudyscotsbonemarrowderivedstemcellsinthetreatmentofagerelatedmaculardegeneration AT stevenlevy stemcellophthalmologytreatmentstudyscotsbonemarrowderivedstemcellsinthetreatmentofagerelatedmaculardegeneration |
_version_ |
1724937556813938688 |